Sumary of Anti-rheumatic drug as a potential candidate for treating COVID-19:
- The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produces inflammatory cytokine storms.
- But an FDA-approved anti-rheumatic drug, Auranofin, used to treat autoimmune and infectious diseases, may also help serve as an antiviral treatment for COVID-19 infection.
- In a new research article, Karine Sonzogni-Desautels and Momar Ndao of the Research Institute of the McGill University Health Centre in Canada make a case for Auranofin based on the drug’s mechanism of action and anti-inflammatory properties via the NF-kBIL-6-STAT3 signaling pathway.
- The researchers write: “An orally-administered FDA-approved drug with anti-inflammatory and anti-SARS-CoV-2 properties with an acceptable toxicity profile would offer significant benefits for the control of the COVID-19 pandemic.
- ” The study “Will Auranofin Become a Golden New Treatment Against COVID-19?” was recently published in the medical journal Frontiers in Immunology.
- Auranofin inhibits several key players in the NF-kB-IL-6-STAT3 signaling pathway Auranofin helps minimize oxidative stress and increases cell survival by inhibiting the thioredoxin reductase enzyme.
- By reducing thioredoxin reductase, Auranofin inhibits NF-kB-dependent gene expression.
- Auranofin is advantageous for its ability to reduce IL-6 expression through inhibition of NF-kb in SARS-CoV-2 infected cells.